Kura falls after downbeat fourth-quarter results
05/03/2026 13:35
** Shares of drugmaker Kura Oncology KURA.O fall 5.80% to $8.05 premarket ** Co posts Q4 loss of 92 cents per share, while analysts were expecting a loss of 61 cents per share, according to data compiled by LSEG ** Posts Q4 revenue of $17.3 million, below analysts' estimate of $53.6 million ** R&D expenses for the quarter were $64.4 million, tied to advancement of combination trials for its blood cancer drug, ziftomenib - KURA ** KURA shares had risen over 19% in 2025 (Reporting by Kunal Das in Bengaluru) ((Kunal.Das2@thomsonreuters.com;))